Pre-Conference Workshop Day
Tuesday, September 15


Taking a Deep Dive into CBD Clinical and Non-Clinical Evidence
08:00 – 11:00 EDT | 5.00 - 8.00 PDT

Take this opportunity to examine amounting clinical and non-clinical CBD evidence with your peers and postulate what findings might mean for the future development of therapeutics with cannabinoid APIs.

Unpick data regarding dosing regimens and routes of administration to address bioavailability and optimize
your product profiles.

In addition, this workshop will explore CBD interactions with the ESC, with debate on what data may be needed to uncover the cellular MOA of CBD to further understanding of the molecule’s clinical potential.

Workshop Leaders:


Allyn Howlett
Wake Forest School of Medicine

Hunter Land

Hunter Land
Associate Director of Cannabinoid Research
Canopy Growth Corporation


Investing and Financing for Early Stage Cannabinoid Drug Developers
08:00 – 11:00 EDT | 5.00 - 8.00 PDT

This workshop will discuss the challenges in obtaining investments for cannabinoid drug development. Attend and equip yourself with the foresight to address financing roadblocks ahead of schedule.

Attend this workshop to discuss:

  •  Traditional drugs vs medical marijuana vs “Consumer and Consumer Health Product”
  • The evolving US regulatory environment and the implications of this for cannabinoid drug development decision makers
  • Analyze why there is a critical need for more robust scientific studies and what more of these could ultimately lead to

Workshop Leader:

Jeff Margolis

Jeff Margolis
Senior Vice President, Chief Financial Officer, Treasurer, Secretary, Board of Directors Member
RespireRx Pharmaceuticals


Nutraceutical Progression and the Approved Botanical FDA route
12:00 – 15:00 EDT | 09.00 - 12.00 PDT

A workshop to take you on a deep dive into cannabinoid application in nutraceuticals, a market forecast tremendous growth over the next few years.

Expert speakers will lead an interactive discussion on:

  • Prescribable & non prescribable – how are medical practitioners responding to the changing landscape?
  • Partnering with private vs academic
  • Novel CBD foods and beverages and their perceived therapeutic value

Workshop Leaders:


Mara Gordon
Aunt Zelda’s

Gavin Clark

Gavin Clark
Managing Director
Delta Eight Pharma


Dr Harry McIlroy
Functional Medicine Practitioner, M.D


Dealing with IP and Market Exclusivity
12:00 – 15:00 EDT | 09.00 - 12.00 PDT

For cannabinoid drug developers the intellectual property landscape is challenging to address.

Despite it being critical for organizations to differentiate themselves in the market, the industry’s guidelines for the creation and protection of IP are still evolving, making this issue difficult to address.

Make sure to join this workshop to get up to speed on

  • IP strategies from pharmaceutical development applicable to CBD based drug development
  • Alternatives to IP protection for securing market exclusivity
  • Hierarchy and strength of protection offered by various IP methods

Workshop Leaders:

Rod Knight

Rod Kight
Kight Law Office

Gregory Gorgas

Greg Gorgas
President and Chief Executive Officer
Artelo Biosciences